Efeitos da metformina no tratamento da obesidade e na resistência à insulina em crianças e adolescentes: Uma Revisão Sistemática
Resumo
Introdução: Obesidade atinge crianças e adolescentes, aumentando a resistência à insulina e risco para DM2. Tratamentos atuais apresentam baixa eficácia em relação à perda de peso.
Objetivo: Avaliar ação da metformina no IMC e na resistência à insulina em crianças e adolescentes obesos.
Materiais e Métodos: Busca nas bases PubMed e MEDLINE, utilizando palavras-chave obesity, metformin, pediatric. Ensaios clínicos randomizados com mais de 3 no escore Jadad foram inclusos.
Resultados: Entre os 5 estudos, a dose máxima foi 2000 mg/dia, de 3 a 6 meses. A diminuição do IMC foi de 1,07 a 1,4 kg/m2 comparado ao controle. Um estudo demonstrou diminuição significativa da resistência à insulina.
Conclusão: A metformina reduz IMC em pacientes obesos, porém não reduz resistência à insulina. Maiores estudos são necessários para identificar candidatos à metformina.
Texto completo:
PDFReferências
Rogovik AL, Chanoine JP, Goldman RD. Pharmacotherapy and weight-loss supplements for treatment of paediatric obesity. Drugs. 2010 Feb 12; 70(3):335-46.
Fleischman A, Rhodes ET. Management of obesity, insulin resistance and type 2 diabetes in children: consensus and controversy. Diabetes Metab Syndr Obes. 2009; 2:185–202.
World Health Organization. World Health Statistics 2009. Disponível em: . Acesso em 7 agost 2009.
Acosta MC, Manubay J, Levin FR. Pediatric obesity: parallels with addiction and treatment recommendations. Harv Rev Psychiatry. 2008; 16(2):80-96.
Glaser Pediatric Research Network Obesity Study Group. Intraperitoneal fat and insulin resistance in obese adolescents. Obesity (Silver Spring). 2010 Feb; 18(2):402-9.
Nammi S. et al. Obesity: an overview on its current perspectives and treatment options. Nutr J. 2004; 3:3.
Marshall SJ. et al. Relationships between media use, body fatness and physical activity in children and youth: a meta-analysis. Int J Obes Relat Metab Disord. 2004; 28(10):1238–46.
Baur LA, Hazelton B, Shrewsbury VA. Assessment and management of obesity in childhood and adolescence. Nat Rev Gastroenterol Hepatol. 2011 Oct 4; 8(11):635-45.
US Preventive Services Task Force. Screening and interventions for overweight in children and adolescents: recommendation statement. Pediatrics. 2005; 116 (1):205-9.
McDonagh MS. et al. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr. 2014 Feb; 168(2):178-84.
Burgert TS. et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes. 2008 Dec; 9(6):567-76.
Weiss R. et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004; 350:2362–2374.
Mauras N. et al. Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat. J Pediatr Endocrinol Metab. 2012; 25(1-2):33-40.
Matson KL, PharmD, Fallon RM. Treatment of Obesity in Children and Adolescents. J Pediatr Pharmacol Ther. 2012; 17(1):45–57.
Centers for Disease Control and Prevention US Department of Health and Human Services. Overweight and Obesity. Disponível em: . Acesso em: 19 nov. 2011.
Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatric Endocrinol Metab. 2008 Apr; 21(4):339-48.
Freemark M. Pharmacologic approaches to the prevention of type 2 diabetes in high risk pediatric patients. J Clin Endocrinol Metab. 2003; 88:3-13.
Ten S, Maclaren N. Insulin resistance syndrome in children. J Clin Endocrinol Metab. 2004; 89:2526-2539.
Decsi T, Molnar D. Insulin resistance syndrome in children: pathophysiology and potential management strategies. Pediatr Drugs. 2003; 5:291-299.
Brufani C. et al. Systematic review of metformin use in obese non diabetic children and adolescents. Horm Res Paediatr. 2013; 80(2):78-85.
US Food and Drug Administration. Orlistat Update Pediatric Advisory Committee Meeting. March 22, 2010. Disponível em: . Acesso em: 25 nov. 2011.
Dolinsky DH, Armstrong SC, Kinra S. The clinical treatment of childhood obesity. Indian J Pediatr. 2013 Mar; 80 Suppl 1:S48-54.
Iughetti L. et al. Pharmacological treatment of obesity in children and adolescents: present and future. J Obes. 2011; 2011:928165.
Wald AB, Uli NK. Pharmacotherapy in pediatric obesity: current agents and future directions. Rev Endocr Metab Disord. 2009 Sep; 10(3):205-14.
Kay JP. et al Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001 Dec; 50(12):1457-61.
Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002; 137:25 – 33.
Prager R, Schernthaner G, Graf H: Effect of metformin on
peripheral insulin sensitivity in non-insulin-dependent mellitus. Diabet Med. 1988; 5:315-319.
Groop L. et al: Different effects of insulin and oral ant-diabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989; 32:599-605.
August GP. et al; Endocrine Society. Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab. 2008; 93:4576–99.
Penildon S. Farmacologia – Rio de Janeiro: Editora Guanabara Koogan, 2010; 8. ed., p.818.
Catoira N. et al. Pharmacological treatment of obesity in children and adolescents: current status and perspectives. Expert Opin Pharmacother. 2010; 11:2973–2983.
Quinn SM. et al. Treatment of clinical insulin resistance in children: a systematic review. Obesity Rev. 2010; 11:722–730.
Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001 Apr; 107(4):E55.
Srinivasan S. et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006 Jun; 91(6):2074-80.
Wilson DM. et al. Glaser Pediatric Research Network Obesity Study Group. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med. 2010 Feb; 164(2):116-23.
Kendall D. et al. Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab. 2013 Jan; 98(1):322-9.
Evia-Viscarra ML. et al. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J Pediatr Endocrinol Metab. 2012; 25(1-2):41-9.
Sociedade Brasileira de Pediatria, Departamento de Nutrologia. Obesidade na infância e adolescência – Manual de Orientação. São Paulo, 2008.
Pereira PF. et al. Circunferência da cintura e relação cintura/estatura: úteis para identificar risco metabólico em adolescentes do sexo feminino? Rev Paul Pediatr. set 2011; 29(3):372-377.
Weiss R. et al. The “obese insulin sensitive” adolescent: importance of adiponectin and lipid partitioning. J Clin Endocrinol Metab. 2005; 90:3731–3737.
Rodriguez G. et al Body composition in adolescents: measurements and metabolic aspects. Int J Obes Relat Metab Disord. 2004; 28(Suppl 3):S54–S58.
Park HS, Lee K. Greater beneficial effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic syndrome: a study of weight reduction programmes in subjects with visceral and subcutaneous obesity. Diabet Med. 2005; 22:266–272.
Vasques ACJ. et al. Análise crítica do uso dos índices do Homeostasis Model Assessment (HOMA) na avaliaçõa da resistência à insulina e capacidade funcional das células-beta pancreáticas. Arq bras endocrinol metab. fev 2008; 52(1):32-39.
Geloneze B, Tambascia MA. Avaliação laboratorial e diagnóstico da resistência insulínica. Arq bras endocrinol metab. abr 2006; 50(2): 208-215.
Apontamentos
- Não há apontamentos.
Direitos autorais 2016 Revista UNILUS Ensino e Pesquisa - RUEP
ISSN (impresso): 1807-8850
ISSN (eletrônico): 2318-2083
Periodicidade: Trimestral
Primeiro trimestre, jan./mar., data para publicação da edição - 30 de junho
Segundo trimestre, abr./jun., data para publicação da edição - 30 de setembro
Terceiro trimestre, jul./set., data para publicação da edição - 31 de dezembro
Quarto trimestre, out./dez., data para publicação da edição - 31 de março
Este obra está licenciado com uma Licença Creative Commons Atribuição-NãoComercial-SemDerivações 4.0 Internacional.
Indexadores
Estatística de Acesso à RUEP
Monitorado desde 22 de novembro de 2016.